{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Intraepithelial+Neoplasia+Grade+II",
    "query": {
      "condition": "Cervical Intraepithelial Neoplasia Grade II"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 46,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Intraepithelial+Neoplasia+Grade+II&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T08:00:11.051Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00003598",
      "title": "UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cervical Cancer",
        "Precancerous/Nonmalignant Condition"
      ],
      "interventions": [
        {
          "name": "tretinoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "14 Years and older · Female only"
      },
      "enrollment_count": 180,
      "start_date": "1999-01",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2010-09-22",
      "last_synced_at": "2026-09-27T08:00:11.051Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003598"
    },
    {
      "nct_id": "NCT03911076",
      "title": "Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ASC-US",
        "ASC-H",
        "LSIL"
      ],
      "interventions": [
        {
          "name": "PVX-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "PapiVax Biotech, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "25 Years to 70 Years · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2019-05-22",
      "completion_date": "2022-06-08",
      "has_results": false,
      "last_update_posted_date": "2024-06-17",
      "last_synced_at": "2026-09-27T08:00:11.051Z",
      "location_count": 6,
      "location_summary": "Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more",
      "locations": [
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Fairfield",
          "state": "Ohio"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Corpus Christi",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03911076"
    },
    {
      "nct_id": "NCT01925378",
      "title": "A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Dysplasia"
      ],
      "interventions": [
        {
          "name": "Nelfinavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2018-11-07",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2020-11-12",
      "last_synced_at": "2026-09-27T08:00:11.051Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01925378"
    },
    {
      "nct_id": "NCT03196180",
      "title": "Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cervical Intraepithelial Neoplasia Grade 2/3",
        "Cervical Squamous Cell Carcinoma In Situ",
        "Cervical Squamous Intraepithelial Neoplasia 2",
        "High Grade Cervical Intraepithelial Neoplasia"
      ],
      "interventions": [
        {
          "name": "Imiquimod",
          "type": "DRUG"
        },
        {
          "name": "Topical Fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 13,
      "start_date": "2019-10-15",
      "completion_date": "2024-08-02",
      "has_results": true,
      "last_update_posted_date": "2025-04-08",
      "last_synced_at": "2026-09-27T08:00:11.051Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03196180"
    },
    {
      "nct_id": "NCT03185013",
      "title": "REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cervical Dysplasia",
        "Cervical High Grade Squamous Intraepithelial Lesion",
        "HSIL"
      ],
      "interventions": [
        {
          "name": "VGX-3100",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Electroporation (EP)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 201,
      "start_date": "2017-06-28",
      "completion_date": "2021-04-06",
      "has_results": true,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-09-27T08:00:11.051Z",
      "location_count": 22,
      "location_summary": "Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Lake Worth",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03185013"
    },
    {
      "nct_id": "NCT01371695",
      "title": "Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cervical Cancer",
        "Cervical Intraepithelial Neoplasia II",
        "Cervical Intraepithelial Neoplasia III"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Onconix, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2011-05",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2011-06-13",
      "last_synced_at": "2026-09-27T08:00:11.051Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01371695"
    },
    {
      "nct_id": "NCT01094132",
      "title": "Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer",
        "Precancerous Condition"
      ],
      "interventions": [
        {
          "name": "Multispectral Digital Colposcope (MDC)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "British Columbia Cancer Agency",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 551,
      "start_date": "2012-12",
      "completion_date": "2016-11-09",
      "has_results": false,
      "last_update_posted_date": "2019-07-05",
      "last_synced_at": "2026-09-27T08:00:11.051Z",
      "location_count": 2,
      "location_summary": "Brooklyn, New York • El Paso, Texas",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01094132"
    },
    {
      "nct_id": "NCT00264732",
      "title": "A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Uterine Cervical Dysplasia"
      ],
      "interventions": [
        {
          "name": "Amolimogene",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "25 Years",
        "sex": "FEMALE",
        "summary": "13 Years to 25 Years · Female only"
      },
      "enrollment_count": 251,
      "start_date": "2005-07",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2013-05-29",
      "last_synced_at": "2026-09-27T08:00:11.051Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00264732"
    },
    {
      "nct_id": "NCT00988559",
      "title": "Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HPV16 Positive",
        "Cervical Intraepithelial Neoplasia (CIN 2/3)"
      ],
      "interventions": [
        {
          "name": "DNA vaccination",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gene gun vaccine",
          "type": "DEVICE"
        },
        {
          "name": "intramuscular vaccination",
          "type": "BIOLOGICAL"
        },
        {
          "name": "intra-lesional vaccine administration",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic resection of the lesion",
          "type": "PROCEDURE"
        },
        {
          "name": "imiquimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 132,
      "start_date": "2009-09",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2018-07-09",
      "last_synced_at": "2026-09-27T08:00:11.051Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00988559"
    },
    {
      "nct_id": "NCT07454915",
      "title": "PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Intraepithelial Neoplasia Grade 2/3",
        "Human Papilloma Virus Infection Type 16"
      ],
      "interventions": [
        {
          "name": "PVX4 Combination Product",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "PapiVax Biotech, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 138,
      "start_date": "2026-04-01",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-09-27T08:00:11.051Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07454915"
    }
  ]
}